Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | BID | P55957 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727408 | 0.86 | GFER (0.41) | HTR2BHTR3ADAOMAOB | |
| SCHEMBL1726725 | 0.86 | HTR2B (0.41) | HTR2BHTR3ADAOMAOB | |
| SCHEMBL1727107 | 0.86 | HTR2B (0.49) | HTR2BHTR3ADAOMAOB | |
| SCHEMBL1727425 | 0.86 | MBOAT4 (0.49) | HTR2BHTR3ADAOMAOB | |
| SCHEMBL1726815 | 0.86 | FFAR1 (0.49) | HTR2BHTR3ADAOMAOB | |
| SCHEMBL1726678 | 0.84 | HTR2B (0.52) | HTR2BHTR3ADAOMAOB | |
| SCHEMBL1726720 | 0.83 | TDP1 (0.45) | HTR2BHTR3ADAO | |
| SCHEMBL1726926 | 0.83 | LMNA (0.51) | HTR2BHTR3ADAOMAOBLMNA | |
| SCHEMBL1727356 | 0.83 | AR (0.43) | HTR2BHTR3A | |
| SCHEMBL1726895 | 0.82 | AR (0.45) | HTR2BHTR3ADAOMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1609798-B1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-1609798-A9 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1609798-A1 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247179-A1 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | SLC5A1, SLC5A2, GPR119 | HTR2B 1490/4885HTR3A 643/4885DAO 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.